Jasper Therapeutics (NASDAQ:JSPR) Issues Quarterly Earnings Results

Jasper Therapeutics (NASDAQ:JSPR) released its earnings results on Thursday. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.17, FiscalAI reports.

Jasper Therapeutics Stock Performance

Shares of NASDAQ JSPR traded down $0.07 during mid-day trading on Friday, reaching $0.79. The company’s stock had a trading volume of 567,510 shares, compared to its average volume of 2,265,872. The stock has a 50-day moving average of $0.59 and a two-hundred day moving average of $0.91. The stock has a market capitalization of $22.12 million, a P/E ratio of -0.24 and a beta of 3.02. Jasper Therapeutics has a 1-year low of $0.32 and a 1-year high of $3.14.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on JSPR shares. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Friday, July 17th. Piper Sandler initiated coverage on shares of Jasper Therapeutics in a research note on Wednesday. They set an “overweight” rating and a $2.00 price target for the company. TD Cowen cut Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Wall Street Zen downgraded Jasper Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Royal Bank Of Canada set a $3.00 price target on shares of Jasper Therapeutics and gave the stock a “sector perform” rating in a research note on Friday, May 15th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $8.17.

Institutional Trading of Jasper Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. grew its holdings in shares of Jasper Therapeutics by 6,394.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,746,492 shares of the company’s stock valued at $3,196,000 after purchasing an additional 1,719,602 shares during the period. Acorn Capital Advisors LLC acquired a new position in Jasper Therapeutics in the third quarter valued at approximately $3,291,000. Velan Capital Investment Management LP grew its position in Jasper Therapeutics by 86.1% in the third quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock worth $6,206,000 after acquiring an additional 1,234,567 shares during the period. Woodline Partners LP acquired a new stake in Jasper Therapeutics during the third quarter worth $2,475,000. Finally, Millennium Management LLC increased its stake in Jasper Therapeutics by 194.2% during the fourth quarter. Millennium Management LLC now owns 1,073,783 shares of the company’s stock worth $1,965,000 after acquiring an additional 708,844 shares during the last quarter. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.